Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.

Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Thermo Fisher launches IVDR-compliant capillary electrophoresis system

May 2025—Thermo Fisher Scientific has introduced the Applied Biosystems SeqStudio Flex Dx genetic analyzer, an IVDR-compliant capillary electrophoresis system for Sanger sequencing and fragment analysis in targeted genomic testing. The system includes three operating modes—in vitro diagnostic use, investigational use only, and research use only—and is available in eight- and 24-capillary configurations. It features four-plate capacity, continuous plate loading with auto-spectral calibration capabilities, and urgent sample reprioritization.

Verichem electrolyte testing reference materials

May 2025—Verichem Laboratories offers liquid stable, multianalyte kits of clinical reference materials intended for the calibration verification of electrolyte assays. The materials are designed to be treated as patient samples for use with systems using flame photometer, direct and indirect ion-selective electrode, or standard enzymatic/colorimetric testing methods. The electrolyte standard kit contains the analytes chloride, ionized calcium, lithium, potassium, and sodium and features a 21-month stability claim; the ISE standard kit contains chloride, lithium, potassium, and sodium and offers an 18-month stability claim. Carbon dioxide assays are covered by the CO2 standard kit and the standalone, ultrahigh CO2 standard level F, which have a 15-month stability claim.

Vitro appoints Biocare Medical as exclusive U.S. distributor

May 2025—Vitro announced it has appointed Biocare Medical (Pacheco, Calif.) as the exclusive distributor of its NeoPath Pro automated staining instrument in the United States. NeoPath Pro is a high-throughput platform with a 42-slide capacity, supporting immunohistochemistry, in situ hybridization, and fluorescence in situ hybridization. The instrument was launched at the USCAP annual meeting in Boston, March 22–27. Vitro is headquartered in Spain.

Vitestro collaborates with Northwestern Medicine

May 2025—Northwestern Medicine and Vitestro announced a multiyear collaboration to advance automation in phlebotomy. As part of the collaboration, Northwestern Medicine will participate in a multicenter clinical trial validating the performance and safety of Vitestro’s Aletta, an autonomous robotic phlebotomy device. The goal of the study is to generate key clinical evidence to support the adoption of automated phlebotomy as a scalable solution for U.S. hospital and outpatient blood draw centers.

Revolutionizing cancer diagnosis: the game-changing role of digital pathology and artificial intelligence

May 2025—Pathology plays a critical role in cancer care, encompassing the development of new treatments, diagnosis, staging, grading of disease, and clinical decision-making. While histopathological slides of tissue biopsies using hematoxylin and eosin staining and immunohistochemical staining remain central to this process, the rise of precision medicine testing is placing greater demands on pathology labs. Health care organizations globally are grappling with ways to address these challenges, mainly due to the declining number of individuals choosing pathology as a specialty. Additional challenges include the rising incidence of cancer, increased testing rates, and the growing complexity of testing. In this evolving landscape, artificial intelligence is emerging to revolutionize pathology, meeting these demands and improving patient outcomes.

Advanced Instruments acquires Nova Biomedical

April 2025—Advanced Instruments, a subsidiary of Patricia Industries, announced the execution of a definitive agreement to acquire Nova Biomedical. Following the close of the transaction, Advanced Instruments and Nova Biomedical will merge and operate under the Nova Biomedical name. Byron Selman, president and CEO of Advanced Instruments, will lead the combined business, while Nova Biomedical founding shareholders Frank Manganaro, CEO, and Dr. Chung-Chang Young, EVP of R&D, will stay with the company in a consulting capacity.

Vitestro unveils Aletta robotic phlebotomy device

April 2025—Vitestro unveiled its CE-marked Aletta Autonomous Robotic Phlebotomy Device. Using AI-driven ultrasound guidance, robotic precision, and full automation, Aletta is designed to perform the entire blood draw process, from applying a tourniquet and preparing the skin to vein identification, venipuncture, automated tube handling, and bandage application. The device integrates advanced AI-driven Doppler ultrasound technology to optimize vein selection and needle placement.

ARUP expands AI-augmented screening tool

April 2025—ARUP Laboratories announced the expansion of its AI-augmented screening tool for the detection of human gastrointestinal parasites to include wet-mount slides. The tool uses scanned images to screen and eliminate negative specimens. It aims to reduce ergonomic stressors on laboratory staff, decrease turnaround time, and increase capacity.

Diasorin C. auris assay launched in countries accepting the CE mark

April 2025—Diasorin announced the launch of its Simplexa C. auris Direct kit in all countries that accept the CE mark. The real-time polymerase chain reaction assay is used for the direct in vitro qualitative detection of C. auris DNA from a composite swab of the axilla and groin from patients suspected of C. auris colonization. The assay detects all six C. auris clades identified worldwide. Results are available in less than two hours on the Liaison MDX.

MARKETPLACE

TRENDING